Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (291-300 of 328) with videos related to

Pageof 33
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapySarah K Jacques, Janet McKeown, Piyush Grover, et al.
Biorxiv : the Preprint Server for Biology|October 4, 2023
Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and TumorSteven M Blum, Daniel A Zlotoff, Neal P Smith, et al.
Circulation|June 17, 2020
Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated MyocarditisLili Zhang, Daniel A Zlotoff, Magid Awadalla, et al.
Journal for Immunotherapy of Cancer|March 5, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review studyElizabeth M Gaughan, Miso Kim, Ignacio Mendez, et al.
Nature|December 12, 2018
Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomasHezhe Lu, Shujing Liu, Gao Zhang, et al.
Nature Medicine|May 4, 2021
Evolution of delayed resistance to immunotherapy in a melanoma responderDavid Liu, Jia-Ren Lin, Emily J Robitschek, et al.
Nature Medicine|June 5, 2025
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanomaKelsey R Monson, Robert Ferguson, Joanna E Handzlik, et al.
Cell|November 3, 2018
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaMoshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, et al.
Journal for Immunotherapy of Cancer|March 7, 2025
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocolsTricia R Cottrell, Michael T Lotze, Alaa Ali, et al.
Journal for Immunotherapy of Cancer|February 24, 2019
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitorsMagid Awadalla, Doll Lauren Alexandra Golden, Syed S Mahmood, et al.
Pageof 33

Showing results (291-300 of 328) with videos related to

Sort By:
Pageof 33
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapySarah K Jacques, Janet McKeown, Piyush Grover, et al.
Biorxiv : the Preprint Server for Biology|October 4, 2023
Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and TumorSteven M Blum, Daniel A Zlotoff, Neal P Smith, et al.
Circulation|June 17, 2020
Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated MyocarditisLili Zhang, Daniel A Zlotoff, Magid Awadalla, et al.
Journal for Immunotherapy of Cancer|March 5, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review studyElizabeth M Gaughan, Miso Kim, Ignacio Mendez, et al.
Nature|December 12, 2018
Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomasHezhe Lu, Shujing Liu, Gao Zhang, et al.
Nature Medicine|May 4, 2021
Evolution of delayed resistance to immunotherapy in a melanoma responderDavid Liu, Jia-Ren Lin, Emily J Robitschek, et al.
Nature Medicine|June 5, 2025
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanomaKelsey R Monson, Robert Ferguson, Joanna E Handzlik, et al.
Cell|November 3, 2018
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaMoshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, et al.
Journal for Immunotherapy of Cancer|March 7, 2025
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocolsTricia R Cottrell, Michael T Lotze, Alaa Ali, et al.
Journal for Immunotherapy of Cancer|February 24, 2019
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitorsMagid Awadalla, Doll Lauren Alexandra Golden, Syed S Mahmood, et al.
Pageof 33